ID   A375-RMR
AC   CVCL_A1VP
SY   A375 RMR; A375 SKIN CJ1; A375-CJ1
DR   cancercelllines; CVCL_A1VP
DR   Cell_Model_Passport; SIDM01935
DR   DepMap; ACH-002001
DR   Wikidata; Q105506031
RX   PubMed=31882401;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:75045; Dabrafenib (Tafinlar; GSK2118436).
CC   Selected for resistance to: ChEBI; CHEBI:75998; Trametinib (Mekinist; GSK1120212).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (DepMap=ACH-002001).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
ST   Source(s): DepMap=ACH-002001
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 11,14
ST   D16S539: 9
ST   D18S51: 12,17
ST   D21S11: 29,30
ST   D3S1358: 15,17
ST   D5S818: 12
ST   D7S820: 9
ST   D8S1179: 11,14
ST   FGA: 22,23
ST   Penta D: 9,15
ST   Penta E: 10,12
ST   TH01: 8
ST   TPOX: 8,10
ST   vWA: 16,17
DI   NCIt; C3802; Amelanotic melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0132 ! A-375
SX   Female
AG   54Y
CA   Cancer cell line
DT   Created: 12-01-21; Last updated: 02-05-24; Version: 8
//
RX   PubMed=31882401; DOI=10.1158/0008-5472.CAN-19-2330;
RA   Melms J.C., Vallabhaneni S., Mills C.E., Yapp C., Chen J.-Y.,
RA   Morelli E., Waszyk P., Kumar S., Deming D., Moret N., Rodriguez S.,
RA   Subramanian K., Rogava M., Cartwright A.N.R., Luoma A., Mei S.-L.,
RA   Brinker T.J., Miller D.M., Spektor A., Schadendorf D., Riggi N.,
RA   Wucherpfennig K.W., Sorger P.K., Izar B.;
RT   "Inhibition of haspin kinase promotes cell-intrinsic and extrinsic
RT   antitumor activity.";
RL   Cancer Res. 80:798-810(2020).
//